Collegium Pharmaceutical (COLL) News Today $29.96 +0.13 (+0.44%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock COLL Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Velan Capital Investment Management LP Purchases New Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Velan Capital Investment Management LP acquired a new stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 28,685 shares of the specialty pharmaceutical company's stock,May 21 at 8:15 AM | marketbeat.comGotham Asset Management LLC Sells 24,032 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Gotham Asset Management LLC decreased its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 46.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 28,074 shares of the specialty pharmaceuticaMay 21 at 4:12 AM | marketbeat.comCollegium Pharmaceutical's (NASDAQ:COLL) Conservative Accounting Might Explain Soft EarningsMay 20 at 10:44 PM | finance.yahoo.comJanus Henderson Group PLC Acquires 221,903 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Janus Henderson Group PLC raised its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 319.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 291,388 shares of the specialty pharmaceutical company'sMay 20 at 4:30 AM | marketbeat.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) have been given an average rating of "Moderate Buy" by the five brokerages that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and four have given a buy recMay 20 at 4:11 AM | marketbeat.comCollegium to Participate in Upcoming Investor ConferencesMay 19 at 4:01 PM | globenewswire.comD. E. Shaw & Co. Inc. Lowers Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)D. E. Shaw & Co. Inc. decreased its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 18.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 217,813 shares of the specialty pharmaceutical company's stock after selling 47,78May 19 at 4:12 AM | marketbeat.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by Comerica BankComerica Bank trimmed its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 54.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 11,278 shares of the specialty pharmaceutical company's stock afMay 19 at 3:30 AM | marketbeat.comNorthern Trust Corp Acquires 20,490 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Northern Trust Corp grew its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 5.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 385,157 shares of the specialty phMay 19 at 3:17 AM | marketbeat.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by Quantedge Capital Pte LtdQuantedge Capital Pte Ltd cut its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 20.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 267,755 shares of the specialty pharmaceutical company's stock afMay 16, 2025 | marketbeat.comCentiva Capital LP Makes New $307,000 Investment in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Centiva Capital LP acquired a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 10,727 shares of the specialty pharmaceuticalMay 15, 2025 | marketbeat.comCollegium Pharmaceutical Announces $25 Million Accelerated Share Repurchase Agreement with Jefferies LLCMay 14, 2025 | nasdaq.com9,804 Shares in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Purchased by Brevan Howard Capital Management LPBrevan Howard Capital Management LP bought a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 9,804 shares of the specialMay 14, 2025 | marketbeat.comCollegium Pharmaceutical enters into accelerated share repurchase agreementMay 12, 2025 | msn.comCollegium Announces $25 Million Accelerated Share Repurchase ProgramMay 12, 2025 | globenewswire.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Acquired by AQR Capital Management LLCAQR Capital Management LLC increased its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 19.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 154,216 shares of the specialty phaMay 12, 2025 | marketbeat.comTruist Financial Sticks to Their Buy Rating for Collegium Pharmaceutical (COLL)May 11, 2025 | theglobeandmail.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comCollegium Pharmaceutical (NASDAQ:COLL) Exceeds Q1 ExpectationsMay 9, 2025 | uk.finance.yahoo.comCollegium pharmaceutical targets $135M in Jornay PM revenue for 2025 amid sales force expansionMay 9, 2025 | msn.comCollegium Pharmaceutical, Inc. (COLL) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comCollegium Pharmaceutical, Inc. 2025 Q1 - Results - Earnings Call PresentationMay 9, 2025 | seekingalpha.comCollegium Reports First Quarter 2025 Financial Results and Highlights Recent Company ProgressMay 8, 2025 | globenewswire.comState of Tennessee Department of Treasury Lowers Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)State of Tennessee Department of Treasury cut its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 52.2% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 8,283 shares of the specialty pharmaceutical company's stock aftMay 8, 2025 | marketbeat.comDimensional Fund Advisors LP Sells 72,840 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Dimensional Fund Advisors LP reduced its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 6.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 975,814 shares of the specialty pharmMay 8, 2025 | marketbeat.com6HROW : Examining the Future: Harrow's Earnings OutlookMay 7, 2025 | benzinga.comCollegium Pharmaceutical (COLL) Q1 Earnings: What To ExpectMay 7, 2025 | finance.yahoo.comFreestone Grove Partners LP Takes $319,000 Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Freestone Grove Partners LP acquired a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 11,141 shares of the specialty pharmaceutical compaMay 7, 2025 | marketbeat.comAquatic Capital Management LLC Invests $461,000 in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Aquatic Capital Management LLC acquired a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 16,089 shares of the specialty phaMay 5, 2025 | marketbeat.comFirst Trust Advisors LP Reduces Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)First Trust Advisors LP reduced its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 8.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 129,691 shares of the specialty pharmaceutical company's stock afterMay 5, 2025 | marketbeat.comWells Fargo & Company MN Sells 9,987 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Wells Fargo & Company MN decreased its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 32.6% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 20,619 shares of the specialty pharmaceutical company's stock after selling 9,987 shareMay 5, 2025 | marketbeat.comCollegium Pharmaceutical (COLL) Projected to Post Earnings on ThursdayCollegium Pharmaceutical (NASDAQ:COLL) will be releasing its Q1 2025 earnings after the market closes on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-collegium-pharmaceutical-inc-stock/)May 3, 2025 | marketbeat.comRaymond James Financial Inc. Invests $2.43 Million in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Raymond James Financial Inc. purchased a new position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 84,883 shares of the specialtyMay 2, 2025 | marketbeat.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Stock Position Lessened by Emerald Mutual Fund Advisers TrustEmerald Mutual Fund Advisers Trust reduced its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 14.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 569,567 shareMay 1, 2025 | marketbeat.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by Fuller & Thaler Asset Management Inc.Fuller & Thaler Asset Management Inc. cut its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 1.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,351,880 shares of the specialty pharmaceApril 27, 2025 | marketbeat.comJPMorgan Chase & Co. Cuts Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)JPMorgan Chase & Co. cut its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 70.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 82,691 shares of the specialty pharmaceutical company'sApril 26, 2025 | marketbeat.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) have been assigned an average rating of "Moderate Buy" from the five brokerages that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and four have given aApril 25, 2025 | marketbeat.comCollegium to Report First Quarter 2025 Financial Results on May 8, 2025April 24, 2025 | globenewswire.comAnalysts Conflicted on These Healthcare Names: Cytokinetics (CYTK) and Teladoc (TDOC)April 21, 2025 | markets.businessinsider.comAlliancebernstein L.P. Sells 66,120 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Alliancebernstein L.P. decreased its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 64.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 36,010 shares of the specialty phaApril 21, 2025 | marketbeat.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by Federated Hermes Inc.Federated Hermes Inc. reduced its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 99.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,067 shares of the specialty pharmaceutical compApril 21, 2025 | marketbeat.comCollegium Pharmaceutical (NASDAQ:COLL) Rating Lowered to "Buy" at StockNews.comStockNews.com downgraded Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Saturday.April 20, 2025 | marketbeat.comInvesco Ltd. Grows Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Invesco Ltd. increased its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 19.5% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 1,775,760 shares of the specialty pharmaceutical company's stock after acquiring an additional 289,335April 18, 2025 | marketbeat.comLSV Asset Management Sells 60,800 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)LSV Asset Management cut its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 13.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 390,451 shares of the specialty phApril 15, 2025 | marketbeat.comMartingale Asset Management L P Cuts Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Martingale Asset Management L P decreased its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 26.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 29,087 shares of the specialtApril 15, 2025 | marketbeat.comWellington Management Group LLP Cuts Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Wellington Management Group LLP trimmed its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 22.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 88,591 shares of the speciaApril 15, 2025 | marketbeat.com2 Reasons to Watch COLL and 1 to Stay CautiousApril 14, 2025 | msn.comF M Investments LLC Acquires Shares of 73,163 Collegium Pharmaceutical, Inc. (NASDAQ:COLL)F M Investments LLC acquired a new position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 73,163 shares of the specialty pharmaceutical company's stock, valuedApril 14, 2025 | marketbeat.comVanguard Group Inc. Sells 63,876 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Vanguard Group Inc. reduced its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 2.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,282,666 shares of theApril 13, 2025 | marketbeat.comCollegium Pharmaceutical (NASDAQ:COLL) Given "Buy" Rating at Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and set a $46.00 price target on shares of Collegium Pharmaceutical in a research report on Wednesday.April 11, 2025 | marketbeat.com Get Collegium Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter. Email Address COLL Media Mentions By Week COLL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. COLL News Sentiment▼1.360.65▲Average Medical News Sentiment COLL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. COLL Articles This Week▼125▲COLL Articles Average Week Get Collegium Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies KRYS News Today SRPT News Today PTCT News Today ACAD News Today CYTK News Today RNA News Today ZLAB News Today SWTX News Today RARE News Today ACLX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:COLL) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Collegium Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Collegium Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
